Why NHS hospital co-morbidity research may be wrong: how clinical coding fails to identify the impact of diabetes mellitus on cancer survival.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
환자: diabetes in each cohort: (1) clinical coding alone, (2) HbA1c blood test alone (3) either clinical coding or abnormal HbA1c
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
This supports the use of more detailed comorbidity data definitions. Results casts doubt over research reliant on hospital clinical coding alone and the generalisability of some comorbidity and frailty scoring systems.
[BACKGROUND] Significant volumes of research rely on secondary care diagnostic coding to identify comorbidities however little is known about its accuracy at a population level or if this influences s
APA
Zucker K, McInerney C, et al. (2025). Why NHS hospital co-morbidity research may be wrong: how clinical coding fails to identify the impact of diabetes mellitus on cancer survival.. British journal of cancer, 133(8), 1137-1144. https://doi.org/10.1038/s41416-025-03136-9
MLA
Zucker K, et al.. "Why NHS hospital co-morbidity research may be wrong: how clinical coding fails to identify the impact of diabetes mellitus on cancer survival.." British journal of cancer, vol. 133, no. 8, 2025, pp. 1137-1144.
PMID
40783629 ↗
Abstract 한글 요약
[BACKGROUND] Significant volumes of research rely on secondary care diagnostic coding to identify comorbidities however little is known about its accuracy at a population level or if this influences subsequent analysis.
[METHODS] Retrospective observational study utilising real world data for all cancers, prostate cancer and breast cancer patients diagnosed at Leeds Cancer Centre from 2005 and 2018. Three different data definitions were used to identify patients with diabetes in each cohort: (1) clinical coding alone, (2) HbA1c blood test alone (3) either clinical coding or abnormal HbA1c. Cohort characteristics, diagnosis dates and Cox derived survival was compared across diabetes definitions.
[RESULTS] 123,841 cancer patients were identified including 13,964 with diabetes. Clinical coding failed to identify 14.6% of diabetic cancer patients with a temporal misclassification rate of 17.5%. Sole reliance on clinical coding overestimated the negative effect of DM on median survival across all cancers and 3.17 years in breast cancer.
[DISCUSSION] Clinical coding provides inaccurate diabetes diagnosis date and detection resulting in meaningful differences in analytic outcomes. This supports the use of more detailed comorbidity data definitions. Results casts doubt over research reliant on hospital clinical coding alone and the generalisability of some comorbidity and frailty scoring systems.
[METHODS] Retrospective observational study utilising real world data for all cancers, prostate cancer and breast cancer patients diagnosed at Leeds Cancer Centre from 2005 and 2018. Three different data definitions were used to identify patients with diabetes in each cohort: (1) clinical coding alone, (2) HbA1c blood test alone (3) either clinical coding or abnormal HbA1c. Cohort characteristics, diagnosis dates and Cox derived survival was compared across diabetes definitions.
[RESULTS] 123,841 cancer patients were identified including 13,964 with diabetes. Clinical coding failed to identify 14.6% of diabetic cancer patients with a temporal misclassification rate of 17.5%. Sole reliance on clinical coding overestimated the negative effect of DM on median survival across all cancers and 3.17 years in breast cancer.
[DISCUSSION] Clinical coding provides inaccurate diabetes diagnosis date and detection resulting in meaningful differences in analytic outcomes. This supports the use of more detailed comorbidity data definitions. Results casts doubt over research reliant on hospital clinical coding alone and the generalisability of some comorbidity and frailty scoring systems.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Comprehensive analysis of androgen receptor splice variant target gene expression in prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.